Mucinous adenocarcinoma of the Prostate -a case report

Djordje Argirovic ,
Djordje Argirovic
Aleksandar Argirovic
Aleksandar Argirovic

Published: 01.12.2014.

Biochemistry

Volume 31, Issue 1 (2015)

pp. 1277-1280;

https://doi.org/10.5937/matmed1501277a

Abstract

Mucinous aenocarcinoma is one of the least common variant of prostate cancer. The prognosis of this variant of prostate cancer remains controversial. We report the case of 67-year old men with severe lower urinary tract symptoms (LUTS), bladder outlet obstruction (BOO), and sense of urinary retention. The serum level of prostate specific antigen (PSA) was 10.4ng/mL. Prostate was large (56mL), hard, lobulated, with extraprostatic extension and infiltration of surrounding structures, unsuitable for radical operative treatment. The patient demonstrated poor response to complete androgen blockade (CAB) (bilateral orchiectomy, steroidal antiandrogen) after 6 months of treatment with minimal decline of PSA (7.1ng/mL) and progressive growth of the primary tumor (110mL). The patient is submitted to antiandrogen withdrawal consisted of simultaneous addition of ketoconazole with hydrocortison substitution, resulting in normalisation of PSA (<1.0ng/mL) and diminution of prostate volume (PV) (63 mL) after 2 months, followed by adjunctive radiotherapy. Ketoconazole in reduced doses was stopped 6 months after completion of radiotherapy with PSA level < 0.002ng/mL and PV 16mL. The patient is alive with no evidence of disease more than 9 years after diagnosis of primary tumor. This case demonstrated modest hormonal sensitivity of mucinous adenocarcinoma of the prostate, whereas ketoconazole combined with radiotherapy, resulted in long term survival.

Keywords

References

1.
Epstein J, Liebermann P. Mucinous adenocarcinoma of the prostatic gland. Am J Surg Pathol. 1985;299–308.
2.
Rhee A, Olgac S, Ohovi M, Russo P. Mucinous adenocarcinoma of the prostate: a case report and a review of literature. Urology. 2004;779–80.
3.
Grignon D. Unusual subtypes of prostate cancer. Mod Pathol. 2004;267–8.
4.
Saito S, Iwaki H. Mucin-producing carcinoma of the prostate: review of 88 cases. Urology. 1999;141–4.
5.
Lane B, Magi-Galluzi C, Reuter A, Levin H, Zhon M, Klein E. Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology. 2006;825–30.
6.
Epstein J, Allabrook W, Jr, Amin M, Egevald L. Concensus conference of Gleason grading of Prostatic Carcinoms. Am J Surg Pathol. 2005;1229–42.
7.
Johnson H, Zhon M, Osunkoya A. ERG expression in mucinous prostatic adenocarcinoma and prostatic adenocarcinoma with mucinous features: comparison with convential adenocarcinoma. Hum Pathol. 2013;2241–6.
8.
Hsuch Y, Tsung S. Prostatic mucinous adenocarcinoma. Urology. 1984;626–7.
9.
Manne R, Haddad F. Mucinous adenocarcinoma of the prostate. Urology. 1989;247–9.
10.
Osunkoya A, Nielsen M, Epstein J. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol. 2008;468–72.
11.
Uchijma Y, Ito H, Takahashi M, Yamachina M. Prostate mucinous adenocarcinoma with signet ring cell. Urology. 1990;267–8.
12.
Osunkoya A, Epstein J. Primary mucin-producing urothelial -type adenocarcinoma of prostate: report of 15 cases. Am J Surg Pathol. 1007;1323–9.
13.
Ro J, Grignon D, Ayala A, Fernandez P, Ordonez N, Wishnow K. Mucinous adenocarcinoma of the prostate: histochemical and immunochistochemical studies. Hum Pathol. 1990;593–600.
14.
Small E, Halabi S, Dawson N, Stadler W, Rini B, Picus J. Antiandrogen withdrawall alone or with combination with ketoconazole in androgen indenpendent prostate cancer patients: a phase III trial (COLGB 9853). J Clin Oncol. 2004;1025–33.

Citation

Copyright

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Partners